Over the last year or so the agency has cleared for market two more ALS drugs. One Relyvrio was developed by Massachusetts based Amylyx Pharmaceuticals. It was approved for the broader ALS population  based on data from a study of about 140 patients that found it offered modest but significant benefits on function and survival